Allogene Therapeutics, Inc. (ALLO) company profile

The company is a clinical-stage biotechnology firm that develops genetically engineered allogeneic T-cell therapies for cancers and autoimmune diseases. Rather than using a patient's own cells, the company engineers donor cells to create standard treatments for broad patient access. Its core product candidates include cemacabtagene ansegedleucel for large B-cell lymphoma, ALLO-316 for renal cell carcinoma, and ALLO-329 for autoimmune conditions such as systemic lupus erythematosus, idiopathic inflammatory myopathies, and systemic sclerosis. The company develops these therapies for individuals diagnosed with blood cancers, solid tumors, and autoimmune disorders.

The company operates an in-house manufacturing facility called Cell Forge 1 in Newark, California, to produce product candidates for its clinical trials. Across six clinical studies, more than 200 patients have received treatment with its cell therapies, and one clinical trial has activated over 60 screening sites. The company holds commercial rights to its primary product candidates in the United States, the European Union, and the United Kingdom, though the provided text does not state its headquarters location.

Summary of the business section of Allogene Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

“The initial public offering price is $18.00 per share of common stock.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

“As of March 2, 2026, the Company had 152 total employees, of which 150 are full-time.”